During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II ...

First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...

First-ever positive profit, entering a new era of growth and global innovation ...

Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced that data from ...

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To ...

Programmed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the body's immune response. While they help prevent autoimmunity, many cancers exploit this ...

Phase III DIPPER trial shows that adjuvant camrelizumab administered after induction-concurrent chemoradiotherapy significantly improved event-free survival in patients with locoregionally advanced ...

Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia ...

- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral ...